Netherlands: More than 1,700 bluetongue infections, South African vaccine not permitted

Published Oct 13, 2023

Tridge summary

The bluetongue virus has spread extensively in the Netherlands, affecting over 1,700 farms, with only one province remaining free from the virus. The Agriculture Minister has stated that there is currently no available vaccine for serotype 3 of the virus, and the South African vaccine, Blu-vax, is not permitted due to safety risks and doubts about its effectiveness. While the search for a vaccine continues, experts do not expect it to have much impact at this point due to the time it takes for animals to build immunity and the decreasing activity of the disease-carrying midges.
Disclaimer:The above summary was generated by Tridge's proprietary AI model for informational purposes.

Original content

The bluetongue virus has now spread widely across the country. The number of farms infected with bluetongue in the Netherlands has increased to more than 1,700. Only the province of Limburg is still bluetongue-free. There does not appear to be a vaccine for the time being, according to the letter to Parliament from Agriculture Minister Piet Adema. Contamination has been detected on the basis of blood samples at more than 1,000 farms, including 700 sheep farms and 300 cattle farms. On the other 700 farms, animals have symptoms consistent with bluetongue, but no blood tests have been carried out. The Minister of Agriculture wrote this in a letter to Parliament. South African vaccine has too many risks In the letter to Parliament, Adema also reports that there is still no vaccine available for serotype 3 of the bluetongue virus. In the Netherlands, only vaccines with serotypes 1, 4 and 8 are permitted. The South African vaccine Blu-vax for sheep contains serotype 3 in addition to ...
Source: Veeteelt

Would you like more in-depth insights?

Gain access to detailed market analysis tailored to your business needs.
By clicking “Accept Cookies,” I agree to provide cookies for statistical and personalized preference purposes. To learn more about our cookies, please read our Privacy Policy.